Global Obesity Drug Sales Expected to Hit $44 Billion by 2030
Bloomberg Intelligence survey credits increased medication access for potential spike.
According to a report by Bloomberg Intelligence, global obesity medication sales could reach $44 billion by 2030, up from $2.5 billion in 2022. Reportedly, analysts believe this will be the result of increased supply, growing demand, and further product innovation.
The organization also credits Novo Nordisk’s Wegovy and Eli Lilly’s tirzepatide with beginning the trend in an out-of-pocket market.
“Unprecedented demand in obesity coupled with the strong relaunch of Wegovy, which serves as a benchmark for future launches, underpins our upgraded sales view for the market,” says Michael Shah, senior industry analyst, Bloomberg Intelligence. “Our previous scenario, published in February, called for $28 billion in obesity sales in 2030, or $33 billion if we don’t adjust for clinical failure risk.”
Reference: Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence. May 31, 2023/Biopharma Reporter
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
